Q2 2024

Filed Aug 13, 2024 · 10-Q · 44 days after period end · 0000950170-24-096185

Q2 2024 · 10-Q

Revenue

$0.00

— vs Q2 2023

Net Income

-$16.31M

N/M vs Q2 2023

EPS Diluted

-$0.23

N/M vs Q2 2023

Operating Income-$17,315,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Revenue	$0.00	$0.00	—	—
Net Income	-$16.31M	-$12.34M	-$12.42M	-$10.39M
EPS Diluted	-$0.23	-$0.22	-$0.44	-$0.64

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR